In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

Etanercept, adalimumab and infliximab all specifically antagonize tumor necrosis factor (TNF), but with differential clinical efficacy. Differences in their pharmacology and mechanisms of action ...

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...

Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 29, 2025, to ...

Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4). Biologics targeting ...

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Immunoinflammatory skin diseases are characterized by an imbalance in immune homeostasis, and their chronic inflammatory processes involve a complex regulatory network of CD4+ T cell differentiation.

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

The key equity indices traded with moderate gains in mid-morning trade, supported by positive global cues. Investors will closely monitor IPO activity, the India-US trade deal, and developments on the ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...